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A novel method to synthesize cyclic oligonucleotides (5- to 26-5 
mer) using the thiol-maleimide reaction is described. The 
target molecules were obtained after subsequent removal of 
thiol and maleimide protecting groups from 5'-maleimido-3'-
thiol-derivatized linear precursors. Retro-Diels–Alder 
conditions deprotecting the maleimide simultaneously 10 
promoted cyclization cleanly and in high yield. 
The advantageous properties of cyclic oligonucleotides with 
respect to linear counterparts (stability to exonucleases, high 
affinity and selectivity in binding target sequences) have turned 
these analogs into tools useful for diagnostics and inhibition of 15 
gene expression (1). Circularity imposes conformational 
restrictions and reduces fraying of internal associations, which 
offers opportunities for assessing enzyme processivity in highly 
demanding conditions (2) as well as for structural studies (3). 
Furthermore, the discovery that small cyclic oligonucleotides are 20 
involved in bacterial metabolism has triggered interest in these 
molecules (4). 
Even though various procedures have been reported, the synthesis 
of cyclic oligonucleotides is still a challenging goal. Cyclization 
reactions have sometimes been carried out on a solid support after 25 
chain assembly (5) or during the deprotection step (6), but most 
often in solution, either chemically or enzymatically. An external 
template placing the two ends close to each other has generally 
been used to obtain circles with more than 30 nucleotides (7). 
Preorganization of linear precursors as hairpins or in multi-30 
stranded structures involving intramolecular interactions (i-motif, 
G-quadruplexes) has also been exploited to favor proximity 
between the two ends (8). Regarding the covalent union and 
depending on the methodology used, circularization has furnished 
either natural phosphodiesters or unnatural linkages (6, 8f, 9). In 35 
the past few years, where the number and variety of applications 
of so-called click reactions (10) has exponentially increased, 
different groups have used the Huisgen cycloaddition to 
synthesize cyclic oligonucleotides with a triazole moiety (8f,11).  
In this manuscript we wish to describe, for the first time, that 40 
cyclic oligonucleotides can also be obtained using the Michael-
type addition of thiols to maleimides, taking advantage of the 
methodology that allows maleimido-oligonucleotides to be on-
resin assembled (12). The key point of this methodology is the 
use of a maleimide protecting group that remains unaltered 45 
during the ammonia-promoted deprotection of oligonucleotide 
functional groups, and which can be subsequently eliminated 
through a retro–Diels-Alder reaction. 
Assessment of whether the thiol-maleimide reaction was suitable 
for oligonucleotide cyclization required synthesis of a linear 50 
oligonucleotide precursor containing masked maleimide and thiol 
functionalities at either end (1, Scheme 1a). Then, two different 
deprotection sequences were examined (Routes A and B, Scheme 
1a) to obtain the target cyclic molecule 5. First experiments were 
carried out with oligonucleotide sequence 55 
5'dGCATGTTTTCATGC (a), which in principle could form 
either a hairpin or a duplex with an internal loop (Figure S4).  
Linear precursor 1a (Scheme 1a) was assembled on a support 
enabling thiol-derivatization of the 3' end (Scheme S1). Chain 
elongation was followed by incorporation of the protected 60 
maleimide at the 5' end using a phosphoramidite derivative now 
also commercially available. Then, treatment with concd. 
aqueous ammonia at room temperature deprotected the 
oligonucleotide functionalities, leaving the maleimide and thiol 
protecting groups unaltered. 65 
As outlined in Route A, the maleimide moiety of oligonucleotide 
1a was first deprotected (heat-promoted retro-Diels–Alder 
reaction) to afford partially protected oligonucleotide 2a. 
Reduction of the disulfide cannot be carried out with a thiol, 
because it would react with the free maleimide. Water-soluble 70 
triscarboxyethylphosphine (TCEP) was chosen as reducing agent. 
Reaction of 2a with a large excess of TCEP (1000 equiv) did not 
provide oligonucleotide 4a (Scheme 1a). The main product in the 
crude was found to have a mass corresponding to [4a + 
P(CH2CH2COOH)3]. 75 
Phosphines, and thus TCEP, are known to exhibit a relatively low 
reactivity towards maleimides, much lower than thiols (13), but 
addition can indeed take place. Taking into account that the 
presence of a proton donor has been described to favor formation 
of fairly stable zwitterionic species (14), a plausible structure for 80 
the first product formed is 6a (Scheme 1b). Zwitterion 6a could 
also form a neutral species with a pentacoordinated phosphorus. 
In slightly basic aqueous solution (conditions suitable for thiol-
maleimide reaction, pH=7.8) this product (6a) was transformed 
into succinimide 7a (as assessed by mass spectrometric analysis). 85 
Reduction to succinimide could plausibly take place as described 
for the reaction of maleimides with triphenylphosphine in MeOH 
(15). 
Use of a lower excess of TCEP (10 equiv) did not provide 4a, but 
a side product whose mass was consistent with a non reduced 90 
disulfide accompanied by TCEP addition to the maleimide. 
Consequently, route A was abandoned to explore route B. 
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Scheme 1. a) Alternatives for the preparation of cyclic oligonucleotides 
from linear precursors 1. b) Undesired reaction of maleimides with TCEP, 
and reduction to succinimide. 5 
Attempts to obtain 4a from 1a in a one-pot experiment (that is, 
thiol deprotection followed by maleimide deprotection without 
any purification) were unsuccessful. Treatment of 1a with TCEP 
afforded 3a, but the crude obtained after subsequent maleimide 
deprotection contained a mixture of 6a and 7a (see structures in 10 
Scheme 1b). Conversely, when disulfide reduction of 1a was 
followed by HPLC purification to remove excess TCEP, 
maleimide deprotection of pure 3a afforded a crude in which the 
main compound (55-60 % by HPLC, data not shown) exhibited 
an m/z ratio corresponding to either 4a or 5a. 15 
This compound remained unaltered after incubation in conditions 
optimal for cyclization (aqueous buffer, slightly basic pH). Since 
in aqueous media maleimido-oligonucleotides are easily 
transformed into products incorporating a water molecule, this 
result suggested that the final compound was likely to be the 20 
cyclic molecule, 5a. It is interesting to notice that MS analysis of 
the crude did not show the presence of dimers or higher 
oligomers. 
Assessment of the structure of the isolated compound was carried 
out taking advantage of the differential reactivity of thiols and 25 
thioethers with H2O2, which oxidizes thiols to sulfonic acids and 
thioethers to sulfoxides (Scheme S2). MS analysis after treatment 
with H2O2 showed that reaction with 3a afforded the sulfonic acid 
(mass increment: 48), while reaction with 5a provided the 
sulfoxide (mass increment: 16). These results confirmed that the 30 
isolated compound was the cyclic oligonucleotide (5a), and 
showed that under the retro-Diels–Alder conditions maleimide 
deprotection was accompanied by cyclization. 
The whole process was repeated (Scheme 1a, route B), with the 
only difference that maleimide deprotection was carried out in a 35 
microwave oven using conditions tested in previous experiments 
(12a). Reproducibility was verified, and in this case the target 5a 
was found to be present in the crude in even higher yield (80-85 
%, HPLC). Hence, use of microwave irradiation to promote the 
retro-Diels–Alder reaction resulted in optimization of the 40 
cyclization methodology. 
It is tempting to hypothesize that intramolecular cyclization might 
be due to oligonucleotide 4a forming a hairpin-type structure 
rather than a duplex-type one (Figure S4), which might facilitate 
formation of dimers, but any of these structures would hardly 45 
survive in the conditions that deprotect the maleimide. In order to 
get more insight into the scope of the method, additional 
experiments were carried out with oligonucleotides 1b, 1c and 
1d. Sequences b (dT10) and c cannot preorganize or fold as a 
hairpin and favor cyclization over oligomerization. End-modified, 50 
CpG-containing 5-mers such as oligonucleotide c (5'dCGTTA) 
have been described to induce apoptosis in leukaemia cell lines 
(16). As to oligonucleotide d, the sequence of this 26-mer is that 
of the trinucleotide repeat present in the 3' UTR region of the 
dystrophia myotonica protein kinase gene (DMPK, located on 55 
chromosome 19), whose expansion leads to the development of 
DM1 (myotonic dystrophy type 1) (17). 
Maleimido- and thiol-protected precursors 1b, 1c and 1d 
(Scheme 1a) were synthesized as described for 1a, and submitted 
to the optimized thiol deprotection/purification/retro-Diels–Alder 60 
reaction series of steps. Again, MS analysis confirmed the 
structure of purified intermediates 3b, 3c and 3d, and that the 
products formed after retro Diels-Alder reaction (5b, 5c, 5d) were 
the cyclic oligonucleotides (there was an increase of 16 mass 
units after reaction with H2O2). These results corroborate the 65 
usefulness of this methodology to prepare cyclic oligonucleotides 
with a 3-thiosuccinimide linkage. It is also worth noticing that 
cyclization yields (68-89 %) were either of the same order as that 
those reported in the literature or superior. 
This work has provided various pieces of evidence. First, that 70 
TCEP does react with free maleimides, furnishing intermediates 
that finally evolve into succinimides. We have also found that 
oligonucleotides with masked maleimides and thiols at either end 
(1) can be cyclized following route B (thiol deprotection followed 
by maleimide deprotection) provided that the excess TCEP used 75 
for disulfide reduction is separated from the [protected 
maleimido]-oligonucleotide-SH (3). Importantly, maleimide 
deprotection and cyclization take place at the same step, and in 
the high dilution reaction conditions (25 µM) the cyclic 
compound is the main one in the crude, as assessed by HPLC. 80 
This methodology has proved useful to obtain small- to medium-
size cyclic oligonucleotides with excellent yield and purity 
regardless of sequence and length, in particular if maleimide 
deprotection and cyclization are carried out in a microwave oven. 
Intramolecular cyclization takes place under conditions (90 oC) 85 
hardly compatible with internal (or external) associations of the 
chain, which precludes internal preorganization or use of an 
external template to bring the ends of the chain close to each 
other. Therefore, formation of the target cyclic oligonucleotide 
seems to be driven essentially by the high dilution of the reaction 90 
medium and the high affinity of thiols for maleimides. 
With very few exceptions (9a, 11a), existing methods not relying 
on structural preorganization have not been able to provide cyclic 
oligonucleotides with more than 20 nucleotides, and cyclization 
yields are often moderate. Commercial synthons exist for the 95 
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preparation of disulfide-bridged cyclic oligonucleotides (9a), but 
when preparing medium size circles (ca 20-mers) by thiol to 
disulfide oxidation, we have often obtained mixtures of 
monomers and dimers even working at oligonucleotide 
concentrations much lower than those recommended (18). 5 
Derivatives for the synthesis of cyclic oligonucleotides using the 
Huisgen cycloaddition are also commercially available. This 
synthetic alternative has furnished the longest circle reported (72-
mer), but the cyclization yield was not provided (11a). 
The methodology here described allows for the straightforward 10 
preparation of cyclic oligonucleotides. We believe it is 
particularly well-suited to prepare medium size circles that would 
be difficult to obtain with all phosphodiester linkages by any 
other approach, and which are conformationally-constrained 
models of non B-DNA structures (5d is an example). All the 15 
necessary synthons are commercially available, and no additional 
reagents such as a metal catalyst are required for the cyclization. 
This is not without importance, because the oligonucleotide may 
be degraded if accompanied by Cu(I) ions (8f). 
We do not know what is the longest oligonucleotide that can be 20 
cyclized using this chemistry, but probably much longer than the 
26-mer here reported. The answer to this question requires 
different procedures to verify that the cyclic molecule has been 
obtained (7c), since the mass spectrometric characterization 
described in this paper is no longer easily feasible. Work is in 25 
progress to further assess the scope of this methodology. 
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